The devices, currently being investigated by teams of heart specialists, could make a big impact in the years ahead. 

The study's authors compared findings from the PROTECT-AF and PREVAIL clinical trials with data from the NCDR LAAO Registry, focusing on short-term and long-term outcomes. 

A late-breaking study at Heart Rhythm 2022 found epicardial ablation in Brugada syndrome helped significantly reduce sudden cardiac arrest in these patients, increasing their survival.

A large proportion of patients with atrial fibrillation (AFib) end up in emergency rooms (ERs), but there are inherent issues with most hospital ERs handing off these patients to electrophysiologists for follow-up care.

“I think he was the most brilliant person I’ve ever met," one long-time colleague said. 

The FDA’s approval was based on data from the EXPLORER-HCM trial, which showed that mavacamten was superior to a placebo for treating obstructive HCM and associated with no significant long-term, treatment-related adverse events.

New research, presented at Heart Rhythm 2022, found a 96% percent freedom from reoccurrence of atrial fibrillation in patients treated with high power vs. standard power radiofrequency ablation.

The new analysis, presented during Heart Rhythm 2022, focused on patients treated at a high-volume facility during the COVID-19 pandemic. 

Heart Rhythm 2022, held from April 28 to May 1 in San Francisco, included a wide range of studies presented by some of the industry's leading specialists. 

Researchers analyzed a total of 21 studies that included more than 107,000 patients who had undergone CT assessments to examine associations between emphysema and lung cancer.

President Joe Biden has responded to a leaked draft majority opinion that reveals the Supreme Court has voted to overturn Roe v. Wade, the court case that allowed legal abortion care in the U.S.